Christopher Wallis, MD, PhD, FRCSC
Christopher Wallis, MD, PhD, FRCSC
Assistant Professor, Division of Urology, University of Toronto
Urologic Oncologist, Division of Urology, Mount Sinai Hospital and University Health Network
Articles by Christopher Wallis, MD, PhD, FRCSC
Drs. Joshua and Wallis contextualize the Metformin Active Surveillance Trial for management of low-risk prostate cancer.
Drs. Morgans, Wallis dissect the association between PSA level of < 0.2 ng/mL and risk of radiological progression in ...
Drs. Soumyajit Roy and Christopher Wallis break down the latest secondary analysis of the SPARTAN trial.
Darolutamide in nmCRPC shows deep PSA responses but some radiographic progression despite low PSA levels.
The MAST trial evaluated metformin’s effects on reducing progression of low-risk prostate cancer during active ...
Drs. Daneshmand and Wallis highlight two trials in progress in NMIBC: ABLE-41 and PIVOT-006.
In patients with high-risk resected UC, adjuvant pembro is associated with improvement in disease-free survival.
Dr. Wallis highlights his population-based research on treatment intensification shortcomings in de novo mCSPC.
Drs. Barata and Wallis highlight the efficacy of pem/len and how this IO/TKI approach compares to other strategies for aRCC.
Drs. Barata and Wallis discuss the interaction of age and benefit of treatment intensification in advanced prostate cancer.
Drs. McGregor and Wallis continue their discussion by pivoting to the BLASST-1 trial.
Drs. McGregor and Wallis highlight CONTACT-2, the first study of an ICI-based regimen to show improvement in rPFS in PC.
Drs. Hoffman and Wallis discuss the HRQoL from FORMULA-509 trial, showing no difference in hormonal function and fatigue.
Dr. Maha Hussain presented results of the BRCAAway trial in patients with mCRPC who have HRR mutations.
Drs. Smith and Wallis shed light on how urologists can reduce risks and improve the well-being of their female patients.
Drs. Freedland and Wallis continue their EMBARK discussions and recommendations for treating high-risk BCR prostate cancer.
Drs. Freedland and Wallis discuss the details of the NEJM phase 3 EMBARK study on enzalutamide in BCR prostate cancer.
The panel conclude with their thoughts on considerations for TURBT and intravesical therapy versus chemoablation.
The panel considers therapies across different risk stratifications, including ATLAS, ENVISION, and BOND-003 studies.
The panel delves into treatment pathways, including considerations for ablation and repeated histologic evaluation.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.